Special Episode: FDA Approves Sodium Oxybate for Pediatric Narcolepsy

Anne Marie Morse, DO, FAASM

A special episode of the NeurologyLive^® Mind Moments^® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments^® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.

This episode, "FDA Approves Sodium Oxybate for Pediatric Narcolepsy," features an exclusive interview with Anne Marie Morse, DO, FAASM, a pediatric sleep disorders specialist, who sat down to discuss the significance of the FDA's expanded indication for sodium oxybate (Lumryz; Avadel Pharmaceuticals) for the treatment of pediatric patients aged 7 years and older with narcolepsy. Morse, director of Child Neurology and Pediatric Sleep Medicine at Geisinger Janet Weis Children's Hospital as well as the program director for Child Neurology Residency Program, provided commentary on the clinical considerations behind this once-nightly formulation of sodium oxybate, and how it should be used going forward. Furthermore, she stressed the careful use of sodium oxybate treatments, noting that they may have significant impact on patients with narcolepsy and should not be only reserved for the most severe cases.

For more of NeurologyLive's coverage of sodium oxybate's expanded approval, head here: FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pedatric Narcolepsy

EPISODE BREAKDOWN

• 2:10 – Immediate reaction and significance 
• 4:10 – Considerations and caution with prescribing sodium oxybate
• 8:20 – Closing remarks and the need to utilize highly effective treatments for narcolepsy

Click here to subscribe to the Mind Moments^® podcast. Be sure to leave a rating and review for the show. Thanks for listening!

REFERENCES
1. Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy. News Release. Avadel Pharmaceuticals. Published October 17, 2024. Accessed October 23, 2024. https://investors.avadel.com/news-releases/news-release-details/avadel-pharmaceuticals-announces-fda-approval-lumryztm-sodium